Hydrocortisone Buteprate topical

Pronunciation

Class: Anti-inflammatory Agents
Note: This monograph also contains information on Hydrocortisone, Hydrocortisone Acetate, Hydrocortisone Butyrate, Hydrocortisone Valerate
ATC Class: D07BB04
VA Class: OR900
CAS Number: 50-23-7
Brands: Ala-Cort, Ala-Scalpt, Analpram-HC, Anucort-HC, Anu-Med HC, Anusert HC, Anusol-HC, Aquanil HC, Caldecort Anti-Itch, Carmol HC, Cetacort, CortaGel Extra Strength, Cortaid Intensive Therapy, Cortaid Maximum Strength, Cortaid Sensitive Skin Formula, Cortenema, Corticaine, Cortifoam, Cortisporin, Cortizone for Kids, Cortizone, Cortizone External Anal Itch Relief, Cortizone Scalp Itch Formula, Dermacort, Dermarest, DriCort, DermiCort, Dermtex HC, Enzone, Epifoam, Gynecort, Hemorrhoidal-HC, Hemril-HC, HydroSKIN, Hytone, LactiCare-HC, Lanacort, Lazersporin-C, Locoid, Mantadil, Massengill Medicated Soft Cloth Towelette, Nupercainal Hydrocortisone Anti-Itch, Nutracort, Orabase HCA, Pandel, Penecort, Pramosone, Preparation H Hydrocortisone, Proctocort, proctocream-HC, proctofoam-HC, Sarnol HC, Scalp-Aid, Scalpcort Maximum Strength, Texacort, Westcort, Zone-A Cream, Zone-A Forte Lotion

Introduction

Corticosteroid secreted by the adrenal cortex; topical anti-inflammatory agent.a

Uses for Hydrocortisone Buteprate

Corticosteroid-responsive Dermatoses

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.b

Nonprescription preparations used for temporary relief of minor skin irritations, itching, and rash caused by eczema, dermatitis, insect bites, poison ivy, poison oak, poison sumac, soaps, detergents, cosmetics, or jewelry.a

Nonprescription preparations used for temporary relief of itchy anal and/or genital areas.a

Nonprescription preparations used for temporary relief of itching and minor scalp irritation caused by scalp dermatitis.a

Generally most effective in acute or chronic dermatoses (e.g., seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).b

Topical therapy generally preferred over systemic therapy; fewer associated adverse systemic effects.b

Slideshow: OTC Medication Use In Pregnancy: Wise or Worrisome?

Topical therapy generally only controls manifestations of dermatoses; eliminate cause if possible.b

Topical efficacy may be increased by using a higher concentration or occlusive dressing therapy. (See Administration with Occlusive Dressing under Dosage and Administration.)b

Response may vary from one topical corticosteroid preparation to another.b

Anti-inflammatory activity may vary considerably depending on the vehicle, drug concentration, site of application, disease, and individual patient.b

Infected Dermatoses

Topical treatment of infected dermatoses in combination with topical anti-infectives (e.g., neomycin, polymyxin B) or antifungals.b

If a topical corticosteroid is used in combination with a topical anti-infective, weigh benefits against risks.b (See Skin Infection under Cautions.)b

Oral Lesions

Hydrocortisone acetate paste used as an adjunct for temporary symptomatic relief of oral inflammatory or ulcerative lesions resulting from trauma.a

Ulcerative Colitis and Anorectal Disorders

Used rectally as a retention enema for adjunctive treatment of mild or moderate acute ulcerative colitis limited to the rectosigmoid or left colon.b

Used rectally as a retention enema for mild acute ulcerative colitis of the transverse or descending colon.b

Retention enema usually is effective in mild or moderate acute rectosigmoid ulcerative colitis when response to sulfasalazine (generally considered the maintenance drug of choice) is inadequate or when sulfasalazine cannot be given.b

Systemic corticosteroids and/or corticosteroid enemas are more effective than sulfasalazine in acute ulcerative colitis attacks, but if surgery is required, it should not be delayed in favor of corticosteroid therapy.b

Hydrocortisone acetate rectal suppositories or suspension (foam), may be effective as adjunctive treatment of rectal ulcerative colitis.b

Hydrocortisone acetate rectal suppositories also are used in the treatment of other anorectal inflammatory conditions (e.g., inflamed hemorrhoids, postirradiation or factitial proctitis, cryptitis, pruritus ani).b

Fixed-combination preparations of a corticosteroid and local anesthetic may be useful for symptomatic relief of anorectal conditions (e.g., hemorrhoids), but combinations with antihistamines, astringents, keratolytics, and/or vasoconstrictors are of questionable efficacy.b

Hydrocortisone Buteprate Dosage and Administration

General

  • Consider location of the lesion and the condition being treated when choosing a dosage form.b

  • Creams are suitable for most dermatoses,b but ointments may also provide some occlusion and are usually used for the treatment of dry, scaly lesions.b

  • Lotions are probably best for treatment of weeping eruptions, especially in areas subject to chafing (e.g., axilla, foot, groin).b Lotions, gels, and aerosols may be used on hairy areas, particularly the scalp.b

  • Formulation affects percutaneous penetration and subsequent activity; extemporaneous preparation or dilution of commercial preparations with another vehicle may decrease effectiveness.b

  • Patients applying a topical corticosteroid to a large surface area and/or to areas under occlusion should be evaluated periodically for evidence of hypothalamic-pituitary-adrenal (HPA)-axis suppression by appropriate endocrine testing (e.g., ACTH stimulation, plasma cortisol, urinary free cortisol).b (See Hypothalamic-Pituitary-Adrenal Axis Suppresion and also Systemic Effects, under Cautions.)

Administration

Topical Administration

For dermatologic use only; avoid contact with eyes.d e

Apply creams, lotions, ointments, solutions, and aerosol foams topically to the skin or scalp.a

Apply paste topically inside the oral cavity.a

Apply rectal creams and ointments externally to the anal area; some commercially available creams also may be applied externally to the anogenital areas.a

The area of skin to be treated may be thoroughly cleansed before topical application to reduce the risk of infection; however, some clinicians believe that, unless an occlusive dressing is used, cleansing of the treated area is unnecessary and may be irritating.b

Apply cream, lotion, ointment, or solution sparingly in a thin film and rub gently into affected area.a

For scalp dermatoses, part the hair and apply small amount of lotion or solution directly to the affected area; rub gently into scalp.a Maintain usual hair care, but do not wash out lotion immediately after application.a Alternatively, for scalp dermatoses, apply aerosol to dry scalp after shampooing.a

To dispense foam, shake container well (for 5–10 seconds) immediately prior to use.f Hold container upright and press down on container cap until foam appears.f Apply a small amount to affected area.f

For use in the mouth, press a small amount of paste to the lesion without rubbing until a thin film develops.a

After a favorable response is achieved, frequency of application or concentration (strength) may be decreased to the minimum necessary to maintain control and to avoid relapse; discontinue if possible.b

Administration with Occlusive Dressing

Occlusive dressings may be used for severe or resistant dermatoses (e.g., psoriasis).a (See Occlusive Dressings under Cautions.)

Soak or wash the affected area to remove scales; apply a thin film of cream, lotion, or ointment; rub gently into the lesion; and apply another thin film.b Cover affected area with a thin, pliable plastic film and seal it to adjacent normal skin with adhesive tape or hold in place with a gauze or elastic bandage.b

If affected area is moist, incompletely seal the edges of the plastic film or puncture the film to allow excess moisture to escape.b For added moisture in dry lesions, apply cream, ointment, or lotion and cover with a dampened cloth before the plastic film is applied or briefly soak the affected area in water before application of the drug and plastic film.b

Thin polyethylene gloves may be used on the hands and fingers, plastic garment bags may be used on the trunk or buttocks, a tight shower cap may be used for the scalp, or whole-body suits may be used instead of plastic film to provide occlusion.b

Frequency of occlusive dressing changes depends on the condition being treated; cleansing of the skin and reapplication of the corticosteroid are essential at each dressing change.b

Occlusive dressing is usually left in place for 12–24 hours and therapy is repeated as needed.b Although occlusive dressing may be left in place for 3–4 days at a time in resistant conditions, most clinicians recommend intermittent use of occlusive dressings for 12 hours daily to reduce the risk of adverse effects (particularly infection) and systemic absorption and for greater convenience.b

The drug and an occlusive dressing may be used at night, and the drug or a bland emollient may be used without an occlusive dressing during the day.b

In patients with extensive lesions, sequential occlusion of only one portion of the body at a time may be preferable to whole-body occlusion.b (See Occlusive Dressings under Cautions.)

Rectal Administration

Administer rectally as a retention enema, suppository, or aerosol foam.a

Administer retention enema, suppository, or foam carefully according to manufacturer’s instructions.a

Dosage

Available as hydrocortisone (dosage expressed in terms of the base) and as hydrocortisone acetate, buteprate, butyrate, and valerate (dosage expressed in terms of the salt).a

Pediatric Patients

Administer the least amount of topical preparations that provides effective therapy.b (See Pediatric Use under Cautions.)

Corticosteroid-responsive Dermatoses
Topical

Nonprescription hydrocortisone preparations should not be used in children <2 years of age unless directed and supervised by a clinician.b

Children ≥2 years of age: Apply appropriate cream, lotion, ointment, or solution sparingly 1–4 times daily.a

Adults

Corticosteroid-responsive Dermatoses
Topical

Apply appropriate cream, lotion, ointment, or solution sparingly 1–4 times daily.a

Apply aerosol foam to affected area 2–4 times daily.a f

Nonprescription preparations should not be used for self-medication for >7 days.a

If the condition worsens or symptoms persist, discontinue and consult a clinician.a

Oral Lesions
Topical

Apply a small amount of paste to the lesion 2 or 3 times daily after meals and at bedtime.a

If substantial regeneration or repair of oral tissues does not occur after 7 days, further investigate etiology of the lesions.a

Ulcerative Colitis and Anorectal Disorders
Rectal (as Retention Enema)

Adjunctive treatment of ulcerative colitis: 100 mg nightly.a Some clinicians recommend 100 mg twice daily followed by 100 mg nightly when improvement occurs.a

Usually given for 21 days or until clinical and proctologic remissions are achieved.a

Lay on left side during and for 30 minutes after administration to distribute drug throughout the left colon.a Retain for ≥1 hour, preferably all night.a

Symptoms may improve in 3–5 days, followed by proctologic improvement.a Discontinue if clinical or proctologic improvement does not occur within 2–3 weeks.a

Protologic remission may require 2–3 months of therapy.a

Following treatment for >21 days, gradually withdraw use; give every other night for 2–3 weeks, then discontinue.a

Rectal (as Foam)

Ulcerative proctitis of the distal rectum: 90 mg (1 applicatorful of a 10% aerosol foam suspension) 1 or 2 times daily for 2–3 weeks.a g Then, if necessary, every other day until clinical and proctologic improvement.a g

Symptoms may improve within 5–7 days.a g

Rectal (as Suppository)

Adjunctive treatment of ulcerative colitis of the rectum and other inflammatory conditions of the anorectum: 25 mg in the morning and at night for 2 weeks.a

Severe proctitis: 25 mg 3 times daily or 50 mg twice daily.a

Adjunctive treatment of postirradiation or factitial proctitis: 25 mg in the morning and at night for 6–8 weeks (or less if an adequate response is attained).a

For internal hemorrhoid symptoms and adjunctive treatment of other anorectal inflammatory conditions: 10 mg in the morning and at night for 2–6 days.a

Prescribing Limits

Pediatric Patients

Corticosteroid-responsive Dermatoses
Self-medication
Topical

Maximum 7 days.a

Adults

Corticosteroid-responsive Dermatoses
Self-medication
Topical

Maximum 7 days.a

Cautions for Hydrocortisone Buteprate

Contraindications

  • Known hypersensitivity to hydrocortisone or any ingredient in the formulation.b d e

  • Rectal corticosteroid therapy in patients with intestinal obstruction, abscess, impending perforation, peritonitis, extensive fistulas, and fresh intestinal anastomoses or sinus tracts.b

Warnings/Precautions

Sensitivity Reactions

Allergic contact dermatitis may manifest as failure to heal rather than irritation as occurs with other topical preparations that do not contain corticosteroids; confirm with diagnostic patch testing.e

General Precautions

Hypothalamic-Pituitary-Adrenal Axis Suppression.

Topically applied corticosteroids can be absorbed in sufficient amounts to reversibly suppress the HPA axis.b

Perform periodic HPA-axis evaluation by appropriate testing (e.g., ACTH stimulation, morning plasma cortisol, urinary free cortisol), especially in patients applying a topical corticosteroid to a large surface area or to areas under occlusion.b

If HPA-axis suppression occurs, withdraw the drug, reduce the frequency of application, and/or substitute a less potent corticosteroid.b

HPA-axis function recovery generally is prompt and complete following drug discontinuance.b

Rarely, glucocorticosteroid insufficiency may require systemic corticosteroid therapy.b

Systemic Effects

Systemic absorption following topical administration may result in manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.b

Adverse systemic effects may occur when corticosteroids are used on large areas of the body, for prolonged periods of time, with an occlusive dressing, and/or concurrently with other corticosteroid-containing preparations.b

Infants and children may be more susceptible to adverse systemic effects.a (See Pediatric Use under Cautions.)

Local Effects

Possible adverse local reactions (e.g., irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae, miliaria); may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.b

Prolonged use of topical corticosteroids may cause atrophy of the epidermis and subcutaneous tissue;b these effects are most likely to occur (even with short-term use) in intertriginous (e.g., axilla, groin), flexor, and facial areas.b

If irritation occurs, discontinue drug and initiate appropriate therapy.b

Skin Infection

If concurrent skin infection is present or develops, initiate appropriate anti-infective therapy.b If infection does not respond promptly, discontinue topical corticosteroid therapy until the infection has been controlled.b

When topical corticosteroids and topical anti-infectives are used concomitantly, consider that the corticosteroid may mask clinical signs of bacterial, fungal, or viral infections; prevent recognition of ineffectiveness of the anti-infective; or suppress hypersensitivity reactions to ingredients in the formulation.b h In addition, consider the cautions, precautions, and contraindications associated with the anti-infective.b h

Do not use occlusive dressings in patients with primary skin infection.b

Some manufacturers state that topical corticosteroids are contraindicated in patients with tuberculosis of the skin, dermatologic fungal infections, and cutaneous or systemic viral infection (including vaccinia and varicella and herpes simplex of the eye or adjacent skin); however, most clinicians believe topical corticosteroids may be used with caution if the infection is treated.b

Severe Ulcerative Colorectal Disease

Use rectally with caution in severe ulcerative disease and only after adequate proctologic examination; risk of intestinal perforation.b

Occlusive Dressings

Adverse systemic corticosteroid effects may occur with use of occlusive dressings on large areas of the body and for prolonged periods of time; monitor accordingly.b (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also Systemic Effects, under Cautions.)

Adverse local reactions may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.b (See Local Effects under Cautions.)

Do not use occlusive dressings on weeping or exudative lesions.b

Do not use occlusive dressings in patients with primary skin infection.b

Remove occlusive dressings covering large areas if body temperature increases; thermal homeostasis may be impaired.b

Use plastic occlusive material with care to avoid the risk of suffocation.b

Use of Fixed Combination

When used in fixed combination with other agents, consider the cautions, precautions, and contraindications associated with the concomitant agents.

Specific Populations

Pregnancy

Category C.c

Lactation

Not known whether topical hydrocortisone is distributed into milk.b Caution advised if topical hydrocortisone is used.b

Pediatric Use

Nonprescription hydrocortisone preparations should not be used in children <2 years of age unless directed and supervised by a clinician.b

Tight-fitting diapers or plastic pants should not be used on a child being treated in the diaper area, since such garments may constitute occlusive dressings.b

Children are more susceptible to topical corticosteroid-induced HPA-axis suppression and Cushing’s syndrome than mature individuals because of a greater skin surface area-to-body weight ratio,b especially when topical corticosteroids are applied to >20% of body surface area.b The risk of adrenal suppression appears to increase with decreasing age.b (See Systemic Effects under Cautions.)

Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol concentrations, and lack of response to corticotropin (ACTH) stimulation.b

Children also are at greater risk of glucocorticoid insufficiency during and/or after withdrawal of treatment.b

Intracranial hypertension has occurred in children; manifestations include bulging fontanelles, headaches, and bilateral papilledema.b

Striae has been reported in children treated inappropriately with topical corticosteroids.b

Topical corticosteroid therapy in children should be limited to the minimum amount necessary for therapeutic efficacy; chronic topical corticosteroid therapy may interfere with growth and development.b

Common Adverse Effects

Burning, stinging, itching, irritation, dry skin, erythema, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.b

Interactions for Hydrocortisone Buteprate

Specific Drugs and Laboratory Tests

Drug or Test

Interaction

Corticosteroids

Potential pharmacologic interaction with other corticosteroid-containing preparationsb

Nitroblue-tetrazolium test for bacterial infection

Concurrent use of corticosteroids reportedly may result in false-negative resultsb

Hydrocortisone Buteprate Pharmacokinetics

Absorption

Bioavailability

Percutaneous penetration of corticosteroids following topical application to the skin varies among individuals and may be increased by occlusive dressings, high corticosteroid concentrations, and certain vehicles.b

Only minimal amounts of topical corticosteroid reach the dermis and subsequently the systemic circulation after application to most normal skin areas; more absorption occurs from the scrotum, axilla, eyelid, face, and scalp than from the forearm, knee, elbow, palm, and sole.b

Absorption is markedly increased by loss of the skin’s keratin layer and by inflammation and/or diseases of the epidermal barrier (e.g., psoriasis, eczema).b

Occlusive dressings used with hydrocortisone for 96 hours substantially enhance percutaneous penetration;b occlusive dressings used for up to 24 hours do not appear to alter penetration.b

In healthy individuals, up to 30–90% of hydrocortisone administered rectally as a retention enema may be absorbed.b Greater amounts of hydrocortisone may be absorbed if the intestinal mucosa is inflamed.b

Distribution

Extent

Not known whether topical hydrocortisone is distributed into milk.b

Elimination

Metabolism

Once absorbed through the skin, topically applied corticosteroids are metabolized primarily in the liver.b

Elimination Route

Topical corticosteroids and metabolites are excreted by the kidneys and, to a lesser extent, in the bile.b

Stability

Storage

Topical

Creams, Lotions, Ointments, Solutions, Aerosol Foams

Room temperature; consult product information for specific recommendations.

Rectal

Creams, Suspensions for Retention Enemas, Aerosol Foams, Suppositories

Room temperature; consult product information for specific recommendations.

Actions

  • Produces anti-inflammatory, antipruritic, and vasoconstrictor actions, possibly resulting in part from steroid receptor binding.b

  • Precise mechanism of action for topical anti-inflammatory activity is unknown; therapeutic benefit in the management of corticosteroid-responsive dermatoses mediated primarily through anti-inflammatory, antipruritic, and vasoconstrictive actions.b d e

  • Anti-inflammatory effects may occur through induction of phospholipase A2 inhibitory proteins (lipocortins); decreased arachidonic acid release from membrane phospholipids.e Decreased arachidionic acid precursors may downregulate biosynthesis of potent inflammatory mediators (e.g., prostaglandins, leukotrienes).e

  • Decreases inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation; and possibly by other mechanisms as yet unknown.b

Advice to Patients

  • Importance of using only as directed, only for the disorder for which it was prescribed, and for no longer than prescribed;b avoid contact with the eyes.d e (See Topical Administration under Dosage and Administration.)

  • Importance of informing patients that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by a clinician.b

  • Importance of informing parents of children receiving the drug that if hydrocortisone is applied in the diaper area, tight-fitting diapers or plastic pants should not be used since they may act as an occlusive dressing.b

  • Importance of reporting any local adverse reactions, especially those occurring under occlusive dressings, to a clinician.b

  • Potential for hydrocortisone acetate suppositories to stain fabric; take appropriate precautionary measures.b

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs; other corticosteroid-containing preparations should not be used without first consulting with clinician.c

  • Importance of women informing clinician if they are or plan to become pregnant or plan to breast-feed.b

  • Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Hydrocortisone

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Rectal

Cream

1%

Proctocort (with benzyl alcohol and propylene glycol)

Monarch

Suspension

100 mg/60 mL

Hydrocortisone Enema

Copley

Topical

Cream

0.5%*

Cortizone-5 (with aloe and parabens)

Pfizer

Cortizone for Kids (with aloe and parabens)

Pfizer

1%*

Ala-Cort

Del-Ray

Cortaid Intensive Therapy (with parabens and propylene glycol)

Pfizer

Cortizone-10 (with aloe and parabens)

Pfizer

Cortizone-10 External Anal Itch Relief Creme (with aloe and parabens)

Pfizer

Dermacort

Melaleuca

DermiCort

Republic

HydroSKIN

Rugby

Hytone (with propylene glycol)

Dermik

Penecort (with benzyl alcohol and propylene glycol)

Allergan

Preparation H Hydrocortisone (with parabens and propylene glycol)

Wyeth

2.5%*

Anusol-HC (with benzyl alcohol and propylene glycol)

Pfizer

Hytone (with propylene glycol)

Dermik

Gel

1%

CortaGel Extra Strength

Norstar

Lotion

0.5%*

HydroSKIN

Rugby

1%*

Ala-Cort

Del-Ray

Aquanil HC (with benzyl alcohol)

Person & Covey

Cetacort (with parabens)

Healthpoint

HydroSKIN

Rugby

LactiCare-HC

Stiefel

Nutracort (with parabens)

Healthpoint

Sarnol HC

Stiefel

2%

Ala-Scalpt

Del-Ray

2.5%

Hydrocortisone Lotion

Glades, Major

Hytone (with propylene glycol)

Dermik

LactiCare-HC

Stiefel

Nutracort (with parabens)

Healthpoint

proctocream-HC (with benzyl alcohol)

Physicians Total Care

Ointment

0.5%*

Cortizone-5

Pfizer

1%*

Cortizone-10

Pfizer

HydroSKIN

Rugby

2.5%*

Hytone

Dermik

Pledgets (saturated with solution)

0.5%

Massengill Medicated Soft Cloth Towelette (with parabens and propylene glycol)

GlaxoSmithKline

Solution

1%

Cortaid FastStick Maximum Strength (with alcohol and methylparaben)

Pfizer

Cortaid Spray Maximum Strength (with alcohol and methylparaben)

Pfizer

Cortizone-10 Scalp Itch Formula Liquid (with alcohol SD 40-2 60% v/v, benzyl alcohol, and propylene glycol)

Pfizer

Penecort (with alcohol SD 40-2 57%, benzyl alcohol, and propylene glycol)

Allergan

Texacort (with SD alcohol 33% and propylene glycol)

Sirius

2.5%

Texacort

Sirius

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Hydrocortisone Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Ointment

1% with Bacitracin Zinc 400 units (of bacitracin) per g, Neomycin Sulfate 0.5% (0.35% of neomycin), and Polymyxin B Sulfate 5000 units (of polymyxin B) per g

Cortisporin

Monarch

1% with Neomycin Sulfate 0.5% (0.35% of neomycin)*

Solution

1% with Neomycin Sulfate 0.5% (0.35% of neomycin), and Polymyxin B Sulfate 10,000 units (of polymyxin B) per g

Lazersporin-C (with propylene glycol)

Pedinol

Hydrocortisone is also commercially available in combination with antihistamines, astringents, keratolytics, local anesthetics, and vasoconstrictors.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Hydrocortisone Acetate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Rectal

Aerosol, foam suspension

10%

Cortifoam (with parabens, propylene glycol, and chlorofluorohydrocarbon propellants)

Schwarz

Suppositories

25 mg

Anucort-HC

G&W

Anu-Med HC

Major

Anusol-HC

Pfizer

Hemorrhoidal-HC

Alpharma, CMC, Sandoz, Rugby, UDL

Hemril-HC Uniserts

Upsher-Smith

Hydrocortisone Acetate Suppositories

IVAX, Paddock, UDL, United Research

30 mg

Proctocort

Monarch

Topical

Cream

0.5%

Corticaine (with parabens)

UCB

0.5% (of hydrocortisone)*

Cortaid Sensitive Skin Formula (with aloe and parabens)

Pfizer

1% (of hydrocortisone)

Caldecort Anti-Itch (with propylene glycol)

Novartis

Cortaid Maximum Strength (with aloe and methylparaben)

Pfizer

Dermarest DriCort

Del

Dermtex HC (with menthol 1%)

Pfeiffer

Nupercainal Hydrocortisone Anti-Itch Cream (with propylene glycol)

Novartis

Lotion

0.5% (of hydrocortisone)*

Ointment

0.5% (of hydrocortisone)

Cortaid Sensitive Skin Formula (with aloe and parabens)

Pfizer

1%

Anusert HC-1

G&W

Gynecort 10

Combe

Lanacort 10

Combe

1% (of hydrocortisone)

Anusol-HC-1

Pfizer

Cortaid Maximum Strength (with aloe and methylparaben)

Pfizer

Paste

0.5%

Orabase HCA

Colgate

Solution

1%

Scalp-Aid

Major

Scalpcort Maximum Strength

Clay-Park

1% (of hydrocortisone)

Dermtex HC Spray

Pfeiffer

Hydrocortisone Acetate Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Rectal

Aerosol, foam suspension

1% with Pramoxine Hydrochloride 1%

proctofoam-HC (with parabens, propylene glycol, and chlorofluorohydrocarbon propellants)

Schwarz

Topical

Aerosol, foam suspension

1% with Pramoxine Hydrochloride 1%

Epifoam (with parabens, propylene glycol, and hydrocarbon propellants)

Schwarz

Cream

0.5% with Chlorcyclizine Hydrochloride 2%

Mantadil (with methylparaben)

GlaxoSmithKline

0.5% with Neomycin Sulfate 0.5% (0.35% of neomycin) and Polymyxin B Sulfate 10,000 units (of polymyxin B) per g

Cortisporin (with methylparaben and propylene glycol)

Monarch

1% with Pramoxine Hydrochloride 1%

Analpram-HC (with propylene glycol)

Ferndale

Enzone (with propylene glycol)

Forest

Pramosone (with propylene glycol)

Ferndale

proctocream-HC (with propylene glycol)

Schwarz

Zone-A Cream (with propylene glycol)

Forest

1% with Urea 10%

Carmol HC (with propylene glycol and sodium metabisulfite)

Doak

2.5% with Pramoxine Hydrochloride 1%

Analpram-HC (with propylene glycol)

Ferndale

Pramosone (with propylene glycol)

Ferndale

Lotion

1% with Pramoxine Hydrochloride 1%

Pramosone (with povidone)

Ferndale

Zone-A Lotion (with povidone)

Forest

2.5% with Pramoxine Hydrochloride 1%

Pramosone (with povidone)

Ferndale

Zone-A Forte Lotion (with povidone)

Forest

Ointment

1% with Pramoxine Hydrochloride 1%

Pramosone

Ferndale

2.5% with Pramoxine Hydrochloride 1%

Pramosone

Ferndale

Hydrocortisone acetate is also commercially available in combination with antihistamines, astringents, keratolytics, local anesthetics, and vasoconstrictors.

Hydrocortisone Buteprate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Cream

0.1%

Pandel (with parabens and propylene glycol)

Savage

Hydrocortisone Butyrate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Cream

0.1%

Locoid (with methylparaben)

Ferndale

Ointment

0.1%

Locoid

Ferndale

Solution

0.1%

Locoid (with isopropyl alcohol 50% and povidone)

Ferndale

Hydrocortisone Valerate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Cream

0.2%

Westcort (with propylene glycol)

Westwood-Squibb

Ointment

0.2%

Westcort (with propylene glycol)

Westwood-Squibb

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Analpram-HC 1-2.5% Cream (FERNDALE LAB): 30/$118.33 or 90/$337.86

Analpram-HC 1-2.5% Lotion (FERNDALE LAB): 59/$116.04 or 177/$324.04

Analpram-HC Singles 1-2.5% Cream (FERNDALE LAB): 120/$232.54 or 360/$654.05

Anusol-HC 2.5% Cream (SALIX PHARMACEUTICALS): 30/$122.42 or 90/$325.26

Anusol-HC 25MG Suppositories (SALIX PHARMACEUTICALS): 12/$55.99 or 24/$96.97

Anusol-HC 25MG Suppositories (SALIX PHARMACEUTICALS): 24/$80.50 or 48/$149.45

Colocort 100MG/60ML Enema (PADDOCK): 60/$15.99 or 180/$35.97

Cortifoam 90MG Foam (MEDA PHARMACEUTICALS): 15/$260.00 or 45/$759.99

Hydrocortisone 0.5% Cream (FOUGERA): 28/$13.99 or 85/$19.97

Hydrocortisone 1% Cream (FOUGERA): 28/$16.99 or 85/$35.97

Hydrocortisone 1% Lotion (FOUGERA): 118/$13.99 or 236/$22.98

Hydrocortisone 100MG/60ML Enema (BRECKENRIDGE): 60/$15.99 or 120/$23.99

Hydrocortisone 2.5% Cream (FOUGERA): 30/$14.99 or 90/$44.97

Hydrocortisone 2.5% Ointment (FOUGERA): 28/$14.99 or 85/$39.97

Hydrocortisone Ace-Pramoxine 1-1% Cream (PERRIGO PHARMACEUTICALS): 30/$79.99 or 90/$219.98

Hydrocortisone Ace-Pramoxine 2.5-1% Cream (ACELLA PHARMACEUTICALS): 28/$49.99 or 85/$139.97

Hydrocortisone Ace-Pramoxine 2.5-1% Cream (PERRIGO PHARMACEUTICALS): 30/$51.99 or 90/$145.97

Hydrocortisone Acetate 1-1% Ointment (PERRIGO): 30/$12.99 or 60/$15.98

Hydrocortisone Acetate 25MG Suppositories (PADDOCK): 12/$15.00 or 24/$20.00

Hydrocortisone Butyrate 0.1% Cream (TARO): 15/$30.99 or 30/$52.87

Hydrocortisone Butyrate 0.1% Cream (TARO): 45/$53.99 or 90/$99.97

Hydrocortisone Butyrate 0.1% Solution (TARO): 60/$27.99 or 180/$59.97

Hydrocortisone Valerate 0.2% Cream (TARO): 15/$22.99 or 30/$35.97

Hydrocortisone Valerate 0.2% Cream (TARO): 45/$34.67 or 135/$100.93

Hydrocortisone Valerate 0.2% Cream (TARO): 60/$45.88 or 180/$129.50

Hydrocortisone Valerate 0.2% Ointment (TARO): 15/$50.99 or 45/$135.97

Hydrocortisone Valerate 0.2% Ointment (TARO): 45/$99.99 or 135/$279.96

Hydrocortisone Valerate 0.2% Ointment (TARO): 60/$119.98 or 180/$321.95

Locoid 0.1% Cream (TRIAX PHARMACEUTICALS): 15/$67.49 or 45/$180.77

Locoid 0.1% Cream (TRIAX PHARMACEUTICALS): 45/$182.99 or 135/$529.96

Locoid 0.1% Ointment (TRIAX PHARMACEUTICALS): 15/$62.04 or 45/$171.18

Locoid 0.1% Ointment (TRIAX PHARMACEUTICALS): 45/$164.29 or 135/$476.78

Locoid Lipocream 0.1% Cream (TRIAX PHARMACEUTICALS): 15/$86.51 or 45/$239.55

Locoid Lipocream 0.1% Cream (TRIAX PHARMACEUTICALS): 45/$230.98 or 90/$448.97

Locoid Lipocream 0.1% Cream (TRIAX PHARMACEUTICALS): 60/$299.78 or 180/$860.83

Pandel 0.1% Cream (PHARMADERM): 15/$77.99 or 45/$215.97

Pandel 0.1% Cream (PHARMADERM): 45/$139.99 or 135/$381.95

Pramosone 1-1% Cream (FERNDALE LAB): 28/$95.33 or 85/$245.45

Pramosone 1-1% Lotion (FERNDALE LAB): 59/$98.90 or 118/$183.98

Pramosone 1-1% Ointment (FERNDALE LAB): 28/$92.05 or 85/$248.37

Pramosone 1-2.5% Cream (FERNDALE LAB): 28/$89.82 or 57/$172.74

Pramosone 1-2.5% Cream (FERNDALE LAB): 57/$117.27 or 171/$346.20

Pramosone 1-2.5% Lotion (FERNDALE LAB): 118/$170.46 or 354/$496.34

Proctocort 1% Cream (SALIX PHARMACEUTICALS): 28/$140.29 or 85/$403.64

ProctoCream-HC 2.5% Cream (ALAVEN PHARMACEUTICAL): 30/$65.98 or 90/$173.06

Proctofoam HC 1-1% Foam (MEDA PHARMACEUTICALS): 10/$79.99 or 30/$219.96

Proctozone-HC 2.5% Cream (RISING PHARMACEUTICALS): 30/$22.99 or 90/$59.97

Vanoxide HC 5-0.5% Kit (SUMMERS LABS): 85/$60.99 or 255/$175.95

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions November 2, 2012. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

a. AHFS drug information 2006. McEvoy GK, ed. Hydrocortisone. Bethesda, MD: American Society of Health-System Pharmacists; 2006: 3471-4.

b. AHFS drug information 2006. McEvoy GK, ed. Topical Corticosteroids General Statement. Bethesda, MD: American Society of Health-System Pharmacists; 2006: 3462-5.

c. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002: 662-70/h.

d. Dermik. Hytone (hydrocortisone) cream and lotion 2.5% prescribing information. Berwyn, PA; 2001 Jun.

e. Westwood-Squibb Pharmaceuticals. Westcort (hydrocortisone valerate) 0.2% cream prescribing information. Princeton, NJ; 2003 Apr.

f. Schwartz. Epifoam (hydrocortisone acetate and pramoxine hydrochloride) foam prescribing information. Milwaukee, WI. 2004 Mar.

g. Schwartz. Cortifoam (hydrocortisone acetate) 10% rectal foam prescribing information. Milwaukee, WI. 2003 Mar.

h. AHFS drug information 2006. McEvoy GK, ed. Neomycin Sulfate. Bethesda, MD: American Society of Health-System Pharmacists; 2006: 2739-40.

Hide
(web3)